Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 neutralizing clones
- Development stage
- Preclinical
- Lead developer
- Kling Biotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Kling Biotherapeutics (formerly AIMM Therapeutics) is developing a program of fully human neutralizing monoclonal antibody clones targeting SARS-CoV-2 antigens for the treatment and prevention of COVID-19. These antibodies are identified using the company's proprietary Kling-Select and Kling-Evolve platforms, which isolate and optimize B cells from 'elite responders'—individuals who have demonstrated exceptionally potent and broad immune responses to the virus. The therapeutic strategy involves the use of these antibodies to bind to viral antigens, such as the spike protein, to neutralize the virus and prevent it from infecting host cells. The program is currently in the lead optimization stage of preclinical development.
- Other names
- SARS-CoV2 neutralizing clonesSARS-CoV-2 neutralizing clonesSARS-CoV 2 neutralizing clonesAIMM Therapeutics SARS-CoV-2 monoclonal antibodies
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on SARS-CoV-2 neutralizing clones.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 neutralizing clones.